Headlines about Celsion (NASDAQ:CLSN) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Celsion earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.9136655164862 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s analysis:
- Hot Stock That Must Be in Your Portfolio – Celsion Corporation (NASDAQ: CLSN) – Alpha Beta Stock (alphabetastock.com)
- Critical Comparison: Celsion (CLSN) versus Edge Therapeutics (EDGE) (americanbankingnews.com)
- Celsion (CLSN) Downgraded by ValuEngine (americanbankingnews.com)
- Celsion Corporation to Present at Upcoming Investor Conferences (finance.yahoo.com)
Celsion (NASDAQ:CLSN) traded up $0.14 during mid-day trading on Friday, reaching $2.58. The company had a trading volume of 264,012 shares, compared to its average volume of 255,807. The stock has a market capitalization of $43.27, a PE ratio of -0.44 and a beta of 1.80. Celsion has a 12-month low of $1.24 and a 12-month high of $6.06.
WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/2018/03/17/celsion-clsn-receives-coverage-optimism-score-of-0-24/2002829.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.